Serious psychiatric adverse events in chronic Hepatitis C patients treated with Pegylated or recombinant Interferon-Alpha plus Ribavirin

被引：0
|
作者：
Drozdz, W. [1 ]
Borkowska, A. [1 ]
Kozielewz, D. [2 ]
Dybowska, D. [2 ]
Ziolkowska-Kochan, M. [3 ]
Halota, W. [2 ]
机构：
[1] Nicholas Copernicus Univ Torun, Clin Neuropsychol Unit, Coll Med, Bydgoszcz, Poland
[2] Nicholas Copernicus Univ Torun, Dept Infect Dis & Hepatol, Coll Med, Bydgoszcz, Poland
[3] Nicolas Copernicus Univ Torum, Dept Clin Neurophysiol, Coll Med, Bydgoszcz, Poland
来源：
EUROPEAN PSYCHIATRY | 2008年 / 23卷
关键词：
D O I：
10.1016/j.eurpsy.2008.01.1268
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：S366 / S367
页数：2
相关论文
共 50 条
  • [1] Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C
    Hadziyannis, S. J.
    Sevastianos, V.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (04) : 491 - 491
  • [2] Serum procalcitonin levels in chronic hepatitis C patients under pegylated interferon-alpha plus ribavirin treatment
    Elefsiniotis, Ioannis S.
    Petrocheilou, Aikaterini
    Scarmeas, Nikolaos
    Ketikoglou, Ioannis
    Pantazis, Konstantinos D.
    Toutouza, Marina
    Tsianos, Epameinondas V.
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2006, 37 (04) : 329 - 331
  • [3] Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C
    Rashed, Yasser K.
    Khalaf, Fatma A.
    Kotb, Sobhy E.
    [J]. CLINICAL AND EXPERIMENTAL PEDIATRICS, 2020, 63 (02) : 52 - 55
  • [4] Autoimmune thyroid diseases in patients with chronic hepatitis C treated by pegylated interferon-alpha and ribavirin - A prospective study
    Ruzic, Maja
    Fabri, Milotka
    Medic-Stojanoska, Milica
    Bajkin, Ivana
    Turkulov, Vesna
    Abenavoli, Ludovico
    [J]. SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2017, 145 (1-2) : 43 - 48
  • [5] PEGYLATED INTERFERON ALPHA PLUS RIBAVIRIN TREATMENT OF CHRONIC HEPATITIS C IN PSORIATIC PATIENTS
    Tomasiewicz, Krzysztof
    Modrzewska, Romana
    [J]. HEPATOLOGY, 2008, 48 (04) : 907A - 907A
  • [6] Improvement in adherence to therapy, adverse events (Aes) and quality of life (QOL) in patients with chronic hepatitis c treated with pegylated interferon plus Ribapak™ compared with pegylated interferon plus ribavirin
    Palmer, Melissa
    [J]. GASTROENTEROLOGY, 2007, 132 (04) : A792 - A792
  • [7] Large Intestine Histopathology of Pegylated-Interferon-Alpha Plus Ribavirin Treated Chronic Hepatitis C Patients
    Pantazis, Konstantinos D.
    Elefsiniotis, Ioannis S.
    Papaioannou, Dimitrios
    Brokalaki, Hero
    Bonatsos, Gerasimos
    Mavrogiannis, Christos
    [J]. GASTROENTEROLOGY RESEARCH AND PRACTICE, 2008, 2008
  • [8] EFFICACY AND SAFETY OF PEGYLATED INTERFERON-ALPHA PLUS RIBAVIRIN COMBINATION THERAPY IN OLD AGE CHRONIC HEPATITIS C PATIENTS
    Dai, C. -Y.
    Huang, C. -F.
    Yu, M. -L
    Huang, J-F
    Chuang, W-L.
    [J]. JOURNAL OF HEPATOLOGY, 2009, 50 : S227 - S227
  • [9] Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply
    Hu, C-C.
    Chien, R-N.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (04) : 492 - 492
  • [10] Pegylated interferon plus ribavirin in chronic hepatitis c
    Bruce R. Bacon
    [J]. Current Gastroenterology Reports, 2001, 3 (1) : 84 - 84
12345